Table 2.
Sero-prevalence for antibodies to H. pylori proteins in relation to colorectal cancer incidence in a nested case-control study within the Southern Community Cohort Study*
| Risk of colorectal cancer | Risk of colon cancer | Risk of rectal cancer | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Controls n (%) | Cases n (%) | Conditional OR (95% CI) | Controls n (%) | Cases n (%) | Conditional OR (95% CI) | Controls n (%) | Cases n (%) | Conditional OR (95% CI) | |
| VacA− | 117 (31.6) | 41 (21.8) | 1.00 (Reference) | 78 (30.1) | 25 (18.9) | 1.00 (Reference) | 33 (36.3) | 13 (28.3) | 1.00 (Reference) |
| VacA+ | 253 (68.4) | 147 (78.2) | 1.84 (1.17, 2.89) | 181 (69.9) | 107 (81.1) | 2.24 (1.22, 4.11) | 58 (63.7) | 33 (71.7) | 1.46 (0.66, 3.22) |
| HP231− | 129 (34.9) | 46 (24.5) | 1.00 (Reference) | 94 (36.3) | 32 (24.2) | 1.00 (Reference) | 30 (33.0) | 12 (26.1) | 1.00 (Reference) |
| HP231+ | 241 (65.1) | 142 (75.5) | 1.74 (1.14, 2.66) | 165 (63.7) | 100 (75.8) | 1.90 (1.15, 3.14) | 61 (67.0) | 34 (73.9) | 1.45 (0.61, 3.43) |
| HP305− | 172 (46.5) | 66 (35.1) | 1.00 (Reference) | 120 (46.3) | 47 (35.6) | 1.00 (Reference) | 41 (45.1) | 16 (34.8) | 1.00 (Reference) |
| HP305+ | 198 (53.5) | 122 (64.9) | 1.63 (1.13, 2.35) | 139 (53.7) | 85 (64.4) | 1.61 (1.04, 2.50) | 50 (55.0) | 30 (65.2) | 1.52 (0.72, 3.22) |
| NapA− | 117 (31.6) | 42 (22.3) | 1.00 (Reference) | 81 (31.3) | 29 (22.0) | 1.00 (Reference) | 29 (31.9) | 11 (23.9) | 1.00 (Reference) |
| NapA+ | 253 (68.4) | 146 (77.7) | 1.67 (1.10, 2.53) | 178 (68.7) | 103 (78.0) | 1.68 (1.03, 2.75) | 62 (68.1) | 35 (76.1) | 1.50 (0.65, 3.47) |
| HcpC− | 229 (61.9) | 96 (51.1) | 1.00 (Reference) | 156 (60.2) | 62 (47.0) | 1.00 (Reference) | 60 (65.9) | 28 (60.9) | 1.00 (Reference) |
| HcpC+ | 141 (38.1) | 92 (48.9) | 1.66 (1.13, 2.43) | 103 (39.8) | 70 (53.0) | 1.89 (1.19, 2.99) | 31 (34.1) | 18 (39.1) | 1.23 (0.57, 2.66) |
| Cad− | 227 (61.4) | 102 (54.3) | 1.00 (Reference) | 157 (60.6) | 71 (53.8) | 1.00 (Reference) | 61 (67.0) | 25 (54.4) | 1.00 (Reference) |
| Cad+ | 143 (38.7) | 86 (45.7) | 1.34 (0.94, 1.92) | 102 (39.4) | 61 (46.2) | 1.34 (0.87, 2.07) | 30 (33.0) | 21 (45.7) | 1.64 (0.81, 3.35) |
| HpaA− | 188 (50.8) | 83 (44.2) | 1.00 (Reference) | 132 (51.0) | 58 (43.9) | 1.00 (Reference) | 49 (53.9) | 22 (47.8) | 1.00 (Reference) |
| HpaA+ | 182 (49.2) | 105 (55.9) | 1.33 (0.93, 1.92) | 127 (49.0) | 74 (56.1) | 1.36 (0.88, 2.11) | 42 (46.2) | 24 (52.2) | 1.26 (0.61, 2.64) |
| Omp− | 114 (30.8) | 48 (25.5) | 1.00 (Reference) | 76 (29.3) | 30 (22.7) | 1.00 (Reference) | 31 (34.1) | 15 (32.6) | 1.00 (Reference) |
| Omp+ | 256 (69.2) | 140 (74.5) | 1.34 (0.88, 2.03) | 183 (70.7) | 102 (77.3) | 1.49 (0.90, 2.49) | 60 (65.9) | 31 (67.4) | 1.05 (0.49, 2.28) |
| UreA− | 211 (57.0) | 96 (51.1) | 1.00 (Reference) | 148 (57.1) | 65 (49.2) | 1.00 (Reference) | 52 (57.1) | 25 (54.4) | 1.00 (Reference) |
| UreA+ | 159 (43.0) | 92 (48.9) | 1.28 (0.90, 1.82) | 111 (42.9) | 67 (50.8) | 1.39 (0.92, 2.12) | 39 (42.9) | 21 (45.7) | 1.10 (0.53, 2.26) |
| Cagδ− | 184 (49.7) | 85 (45.2) | 1.00 (Reference) | 132 (51.0) | 57 (43.2) | 1.00 (Reference) | 47 (51.7) | 23 (50.0) | 1.00 (Reference) |
| Cagδ+ | 186 (50.3) | 103 (54.8) | 1.18 (0.83, 1.68) | 127 (49.0) | 75 (56.8) | 1.35 (0.88, 2.07) | 44 (48.4) | 23 (50.0) | 1.04 (0.52, 2.11) |
| CagM− | 143 (38.7) | 67 (35.6) | 1.00 (Reference) | 101 (39.0) | 46 (34.9) | 1.00 (Reference) | 34 (37.4) | 18 (39.1) | 1.00 (Reference) |
| CagM+ | 227 (61.4) | 121 (64.4) | 1.18 (0.79, 1.74) | 158 (61.0) | 86 (65.2) | 1.26 (0.78, 2.04) | 57 (62.6) | 28 (60.9) | 0.93 (0.44, 1.96) |
| HyuA− | 199 (53.8) | 98 (52.1) | 1.00 (Reference) | 139 (53.7) | 72 (54.6) | 1.00 (Reference) | 47 (51.7) | 22 (47.8) | 1.00 (Reference) |
| HyuA+ | 171 (46.2) | 90 (47.9) | 1.07 (0.76, 1.52) | 120 (46.3) | 60 (45.5) | 0.97 (0.64, 1.47) | 44 (48.4) | 24 (52.2) | 1.18 (0.56, 2.50) |
| GroEL− | 79 (21.4) | 38 (20.2) | 1.00 (Reference) | 52 (20.1) | 25 (18.9) | 1.00 (Reference) | 22 (24.2) | 12 (26.1) | 1.00 (Reference) |
| GroEL+ | 291 (78.7) | 150 (79.8) | 1.08 (0.69.1.70) | 207 (79.9) | 107 (81.1) | 1.10 (0.63.1.92) | 69 (75.8) | 34 (73.9) | 0.89 (0.39, 2.02) |
| Catalase− | 178 (48.1) | 89 (47.3) | 1.00 (Reference) | 133 (51.4) | 57 (43.2) | 1.00 (Reference) | 37 (40.7) | 26 (56.5) | 1.00 (Reference) |
| Catalase+ | 192 (51.9) | 99 (52.7) | 1.05 (0.73, 1.51) | 126 (48.7) | 75 (56.8) | 1.43 (0.93, 2.22) | 54 (59.3) | 20 (43.5) | 0.51 (0.24, 1.10) |
| CagA− | 115 (31.1) | 59 (31.4) | 1.00 (Reference) | 81 (31.3) | 37 (28.0) | 1.00 (Reference) | 28 (30.8) | 20 (43.5) | 1.00 (Reference) |
| CagA+ | 255 (68.9) | 129 (68.6) | 0.99 (0.64, 1.53) | 178 (68.7) | 95 (72.0) | 1.26 (0.74, 2.16) | 63 (69.2) | 26 (56.5) | 0.47 (0.20, 1.12) |
*
Results are from a conditional logistic regression model, among cases and controls matched on age, race, sex, menopausal status (for women), CHC site, date of sample collection, and availability of serum, assessing the association of sero-positivity to each H. pylori protein, in separate models, with odds of incident colorectal cancer.
NOTE: Bold indicates statistically significant at P < 0.05.